分组1 - X4 Pharmaceuticals reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.36, and a significant improvement from a loss of $6.01 per share a year ago, resulting in an earnings surprise of +38.89% [1] - The company achieved revenues of $2.57 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 53.22%, compared to revenues of $1.43 million in the same quarter last year [2] - X4 Pharmaceuticals has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed the market, losing about 11% since the beginning of the year, while the S&P 500 has declined by 2.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.23 on revenues of $4.9 million, and for the current fiscal year, it is -$1.09 on revenues of $11.25 million [7] - The Medical - Biomedical and Genetics industry, to which X4 Pharmaceuticals belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - X4 Pharmaceuticals is progressing with its pivotal 4WARD Phase 3 trial for chronic neutropenia, aiming for enrollment completion by Q3 2026 [1][2] - The European Medicines Agency has issued a positive opinion recommending marketing authorization for mavorixafor to treat WHIM syndrome in the EU [1][2] - The company has sufficient cash runway through 2028, supported by recent equity financings and operational cost reductions [1][4] Recent Accomplishments and Updates - The 4WARD trial is focused on evaluating mavorixafor's efficacy, safety, and tolerability in patients with chronic neutropenia, with over 100 active clinical trial sites established [6][8] - The positive opinion from the EMA will be reviewed by the European Commission, with a final decision expected in Q2 2026 [6][8] - The company has implemented measures to enhance trial enrollment, including expanding clinical sites and increasing physician engagement [6] Financial Results - For Q4 2025, net product sales were $2.3 million, and for the full year, they reached $6.5 million, primarily from XOLREMDI sales in the U.S. [4][13] - Total revenue for Q4 2025 was $2.6 million, while for the full year, it was $35.1 million [4][13] - The operating loss for Q4 2025 was $23.7 million, with a net loss of $23.9 million, or $(0.22) per share [4][13] Balance Sheet Overview - As of December 31, 2025, cash and cash equivalents totaled $217.0 million, with total assets amounting to $290.5 million [4][14] - The company reported total stockholders' equity of $186.3 million, indicating a strong financial position [4][14]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the annual period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38295 _____________________________________________________________________________________ X4 PHARMACEUTICA ...

Summary of X4 Pharmaceuticals Conference Call Company Overview - **Company**: X4 Pharmaceuticals - **Ticker**: NasdaqCM:XFOR - **Industry**: Rare Hematology Diseases - **Focus**: Development of mavorixafor for chronic neutropenia, previously approved for WHIM (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) [2][3] Key Points and Arguments Management Changes and Strategy - A new management team was established in 2025, focusing on reducing costs and headcount while prioritizing the execution of the pivotal 4WARD trial for mavorixafor [2][5] - The aim is to complete enrollment in the 4WARD trial by Q3 2026, with data readout expected in 2027 and potential commercialization in 2028 [3][6] Market Opportunity - Chronic neutropenia affects approximately 50,000 Americans, with 15,000 being the target population for mavorixafor, specifically those with severe and moderate chronic neutropenia (ANC < 1,000) [10][11] - Current standard of care includes G-CSF, which is used by about 40% of patients, but has limitations such as side effects and the risk of long-term complications [14][15] - Mavorixafor is an oral agent with a favorable side effect profile, presenting a significant market opportunity to replace or complement G-CSF [15][16] Clinical Trial Insights - The 4WARD trial is a double-blind, placebo-controlled study with 176 patients, focusing on reducing infections and increasing ANC as co-primary endpoints [41][42] - The trial design includes independent adjudication of infections to ensure data consistency and reliability [55][56] - Preliminary phase 2 data indicated that mavorixafor can be safely administered with G-CSF, with a significant reduction in G-CSF dosage observed [29][34] Safety and Efficacy - The drug has shown a good safety profile, with manageable gastrointestinal side effects [36][37] - The company aims to demonstrate improvements in quality of life and fatigue as secondary endpoints in the upcoming trial [64][65] Commercialization Plans - X4 Pharmaceuticals plans to launch mavorixafor in the second half of 2028, with sufficient funding secured for commercialization efforts [69][70] - The company is focusing on educating healthcare providers about mavorixafor to facilitate adoption, especially among patients intolerant to G-CSF [70][72] Regulatory and Intellectual Property - The company holds a composition of matter patent extending to 2038, with potential for additional patents to extend exclusivity to 2041 [97][100] - X4 Pharmaceuticals is also pursuing regulatory approval in Europe, with a positive CHMP opinion received for WHIM [88][89] Additional Important Information - The company has deprioritized WHIM commercialization efforts to focus resources on chronic neutropenia [78] - There is an ongoing effort to generate real-world data and investigator-initiated studies (ISTs) to expand knowledge and usage of mavorixafor [92] - The management team has a history of successfully commercializing drugs in rare hematology, enhancing confidence in the execution of their strategy [53][71]

Core Viewpoint - Analyst sentiment has turned positive for X4 Pharmaceuticals, Immuneering, and Tango Therapeutics, with new or maintained Buy ratings ahead of pivotal clinical trial readouts in 2026 [1] Group 1: Company Summaries - **X4 Pharmaceuticals (XFOR)**: Received a Buy rating from Guggenheim with a price target of $12, indicating significant upside from the current trading price of $3.97. The company raised $240.3 million, extending its cash runway to the end of 2028, and is focused on mavorixafor, a potential first-in-class oral CXCR4 antagonist [1] - **Immuneering (IMRX)**: Maintained an Overweight rating from Piper Sandler with a revised price target of $12, down from $13. The company is on track for key clinical catalysts, including updated ctDNA data and Phase 2a survival data in pancreatic cancer expected in 2026 [1] - **Tango Therapeutics (TNGX)**: Stifel raised its price target to $24 from $15 while maintaining a Buy rating. The company has seen a significant stock increase of 87.25% year-to-date and is preparing for a pivotal study in pancreatic cancer [1] Group 2: Market Performance and Analyst Ratings - All three companies have received Buy or Overweight ratings from analysts, with substantial gaps between current trading prices and analyst targets, reflecting the binary nature of clinical-stage biotech [1] - X4 Pharmaceuticals has a consensus target of $9.33, more than double its current share price, while Immuneering has gained 257.24% over the past year but is down 17.48% year-to-date [1] - Tango Therapeutics is trading close to its 52-week high, indicating that much of the near-term re-rating has already occurred, with 10 of 11 analysts rating it a Buy or Strong Buy [1]

Company Overview - X4 Pharmaceuticals focuses on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs [2] - The company has developed mavorixafor, an orally available CXCR4 antagonist, which is commercially available in the U.S. as XOLREMDI® for its first indication [2] - X4 is conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders [2] - The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia [2] - X4 Pharmaceuticals is headquartered in Boston, Massachusetts [2] Upcoming Events - The management team of X4 Pharmaceuticals will participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026, at 10:00 a.m. ET in Miami, FL [1] - A link to the live and archived webcast will be available on X4 Pharmaceuticals' website under the Investors section: Events and Presentations [1]

After years of volatility and a brutal post-COVID correction, biotech investors have understandably become more selective. In the current climate, investors are looking for companies with funded clinical trials, tangible product pipelines, and balance sheets that don’t requireAt Avalon Capital Research, our mission is straightforward: deliver independent, actionable research on U.S.-listed companies and the forces that move markets. We believe investors deserve clarity, not noise, when it comes to earnings ...

Core Insights - X4 Pharmaceuticals has issued inducement awards to new employees under the 2019 Inducement Equity Incentive Plan, granting options to purchase 24,000 shares of common stock [1][2] Company Overview - X4 Pharmaceuticals focuses on improving the lives of individuals with rare hematology diseases by developing innovative therapies [3] - The company has developed mavorixafor, an orally available CXCR4 antagonist, which is commercially available in the U.S. as XOLREMDI [3] - X4 is conducting a pivotal Phase 3 clinical trial (4WARD) for mavorixafor in chronic neutropenic disorders, with Fast Track designation granted by the U.S. FDA for this treatment [3] Inducement Awards Details - The options granted have a ten-year term and an exercise price of $3.44 per share, equal to the closing price on February 27, 2026 [2] - Each option will vest over a four-year period, with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months, contingent on continued employment [2]

- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization, under exceptional circumstances, of mavorixafor for the treatment of WHIM syndrome ...

Core Perspective - The company aims to be a leader in developing new therapies for patients with rare blood disorders, specifically focusing on mavorixafor for chronic neutropenia [2]. Group 1: Company Strategy - The management team has been in place for about 6 months, concentrating efforts on achieving the company's goals [1]. - Significant cost reductions and headcount decreases have been implemented to streamline operations [3]. - The primary focus is on successfully completing the Phase III trial to bring the new indication to patients [3].